A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platfo...

Full description

Bibliographic Details
Main Authors: I-Jung Lee, Yu-Hua Lan, Ping-Yi Wu, Yan-Wei Wu, Yu-Hung Chen, Sheng-Che Tseng, Tzu-Jiun Kuo, Cheng-Pu Sun, Jia-Tsrong Jan, Hsiu-Hua Ma, Chun-Che Liao, Jian-Jong Liang, Hui-Ying Ko, Chih-Shin Chang, Wen-Chun Liu, Yi-An Ko, Yen-Hui Chen, Zong-Lin Sie, Szu-I Tsung, Yi-Ling Lin, I-Hsuan Wang, Mi-Hua Tao
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Nanoparticle vaccine
SARS-CoV-2
COVID-19
durable antibody response
cross-protectivity
variants of concern
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2149353

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2149353

Similar Items